Pemigatinib Pill
Sponsors
Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital
Conditions
Breast CancerGastrointestinal Cancer
Phase 2
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
NCT05560334
Start: 2022-09-08End: 2025-09-08Target: 20Updated: 2022-09-29
A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy
NCT05559775
Start: 2022-08-10End: 2025-08-10Target: 20Updated: 2022-09-29